Therefore, as a mitochondrial ribosomal protein that can be regulated by hyperglycemia, the effect of MRPS6 on improving insulin secretion and reducing ROS level is similar to that of metformin (Lu et al., 2016), which is currently a clinical hypoglycemic drug, suggesting that MRPS6 can be used as a new target for combination therapy. This evidence concerns the gene INS and Hyperglycemia.